ARTICLE | Product Development
Telix’s end-to-end radiopharma ambitions
With a NASDAQ listing, diagnostic revenues, and clinical therapeutics, logistics-forward company aims to own entire disease journey
March 6, 2025 9:58 PM UTC
While most radiopharma companies are focused on a particular radioisotope platform or ligand modality, Telix is using a range of technologies to tailor therapeutic-diagnostic pairs for specific indications. Through acquisitions, partnerships and internal R&D, the 1,100-person company aims to build a “whole solution” logistics infrastructure that spans from isotope production, to nuclear medicine sales, to last-mile delivery.
Founded in 2015 and incorporated in 2017, Melbourne-based Telix Pharmaceuticals Ltd. (ASX:TLX; NASDAQ:TLX) has been amassing assets and capabilities to diagnose and treat cancers using radioactive agents whose manufacturing processes and decay kinetics require fast, sophisticated supply chains. ...